Concurrent Bacterial and mRNA Vaccination for Dual Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunization regimens for bacterial and COVID-19 infections, particularly in elderly and infant subjects, do not effectively enhance the immune response when combining protein/polysaccharide-based vaccines with nucleic acid-based vaccines, leading to suboptimal protection against pneumococcal diseases and COVID-19.
Innovation Solution
Concurrent or concomitant administration of a first immunogenic composition containing bacterial antigens (polypeptides, toxoids, or polysaccharides) with a second immunogenic composition comprising mRNA vaccines, specifically targeting bacterial pathogens and betacoronaviruses like SARS-CoV-2, to enhance the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein and/or polysaccharide antigens from pathogens are used in vaccines, then neutralizing antibody and cell-mediated immune responses are elicited, but the immune response may be insufficient when combined with nucleic acid-based vaccines
Solution Approach 1:
The patent combines protein/polysaccharide-based bacterial vaccines with nucleic acid-based COVID-19 vaccines in a single immunization regimen. The bacterial vaccine component (containing polypeptide and/or polysaccharide antigens) is administered concurrently with the mRNA vaccine, creating a combined vaccine formulation that addresses both bacterial infections and COVID-19 simultaneously, thereby resolving the contradiction between maintaining effective immune responses and improving adaptability across different pathogen types
Solution Approach 2:
The combined vaccine formulation serves multiple protective functions: the protein/polysaccharide component provides immunity against bacterial pathogens while the nucleic acid component provides immunity against COVID-19. This multi-functional approach allows a single immunization regimen to address diverse pathogen threats, improving the overall adaptability and versatility of the vaccination strategy
2Reliability
If nucleic acid-based vaccines are used, then cell-mediated immunity is elicited, but antibody production may be insufficient without complementary components
Solution Approach 1:
The patent merges nucleic acid-based vaccines (which provide cell-mediated immunity through effector T-cells) with protein/polysaccharide-based vaccines (which provide antibody production). The combined formulation ensures that both immune components are present: the nucleic acid component generates T-cell responses while the protein/polysaccharide component stimulates antibody production, thereby resolving the contradiction between cell-mediated immunity and antibody quantity
Solution Approach 2:
The vaccine formulation uses a composite approach by combining different vaccine components (nucleic acid and protein/polysaccharide) in a single regimen. This composite material strategy allows the formulation to simultaneously provide both cell-mediated and humoral immunity, addressing the limitation of nucleic acid-based vaccines alone in producing sufficient antibodies
3Reliability
If existing immunization regimens are used for bacterial and COVID-19 infections, then protection is provided, but the immune response is suboptimal compared to enhanced combinations
Solution Approach 1:
The patent merges separate immunization regimens for bacterial infections and COVID-19 into a single combined formulation. By administering the bacterial vaccine (protein/polysaccharide) and COVID-19 vaccine (nucleic acid) concurrently, the system achieves enhanced immune response magnitude while maintaining protection against both pathogen types, thereby resolving the contradiction between providing protection and maximizing immune response productivity
Data Source
AI summary
The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.